Our fundamental premise is that innovative methods, analytical rigor, and scientific acumen can be provided in a commercial entity that operates “at the speed of business.” Monument Analytics delivers.

Unparalleled Knowledge Base

One of the most remarkable features of Monument Analytics is its access to consultants with an unparalleled knowledge base. Through its independent consulting services, Monument Analytics leverages this acumen to assist clients developing products and services for the benefit of society.

Top Notch Evidence

By capitalizing on this unparalleled depth and breadth of human capital, Monument Analytics is able to generate the highest quality evidence regarding the safety, effectiveness, and real-world value of the full range of medical processes and technologies; and to use this knowledge to help our clients navigate evermore complex and challenging regulatory and payment environments.

Internationally Renowned Experts

Our Principals and Consultants are internationally renowned for their expertise in areas ranging from epidemiology and biostatistics to clinical fields such as cardiovascular medicine, oncology, and immunology.

G. Caleb Alexander
G. Caleb AlexanderMD, MS
Jonothan C. Tierce
Jonothan C. TierceCPhil
William V. Padula
William V. PadulaPhD
Natalie Reid
Natalie ReidPhD, MPH, MBA


Our services are broadly organized into four core capabilities

  • Comparative effectiveness analyses
  • Pharmacovigilance and safety assessments
  • Investigations of drug utilization
  • Risk-benefit appraisals
  • Bayesian, meta-analytic and systematic reviews
  • Patient and clinician preferences
  • Global marketplace and pharmaceutical policy
  • Design and conduct of sophisticated comparative effectiveness, pharmacovigilance, and drug utilization studies
  • Advanced techniques for causal inference, management of missing data, and other statistical analysis
  • Cost-benefit analysis and cost-effectiveness analysis
  • Natural history of disease and resource utilization
  • Systematic economic and quality-of-life reviews
  • Core value dossiers

MA in the News

November 6, 2020
Caleb Alexander
Monument Analytics Principal Dr. Caleb Alexander was quoted in The New York Times Article: “F.D.A. Panel Declines to Endorse Controversial Alzheimer’s Drug” for his participation on the federal panel of experts assessing aducanumab for treatment of Alzheimer’s disease.

November 4, 2020
Monument Analytics
The Monument Analytics Team co-authored a piece in JAMA Network Open titled: “Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality.”

October 22, 2020
Caleb Alexander
Monument Analytics Principal Dr. Caleb Alexander was interviewed on Bloomberg Businessweek’s “Why Telemedicine Might Not Work for Everything.”

October 17, 2020
Bill Padula
Monument Analytics Principal Dr. Bill Padula was cited in The Regulatory Review Saturday Seminar Article: “Regulating Prescription Drug Costs” for his article from the Journal of Health Care Law and Policy titled: “State and Federal Policy Solutions to Rising Prescription Drug Prices in the U.S.”

October 14, 2020
Caleb Alexander
Monument Analytics Principal Dr. Caleb Alexander was interviewed by Verywell Health about challenges with telemedicine.

October 13, 2020
Caleb Alexander
Dr. Caleb Alexander’s paper, “Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US” in JAMA Network Open was featured in several news outlets including Medpage Today’s article “Cardiovascular Screenings Fall as Telehealth Moves In” and in Healio, “Despite surge in telehealth, primary care visits drop 21% amid COVID-19.”